⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21648235 | 0.77 | GABRP (0.39) | — | |
| SCHEMBL8576969 | 0.74 | SMN1; SMN2 (0.49) | — | |
| SCHEMBL12216360 | 0.74 | SMN1; SMN2 (0.42) | — | |
| SCHEMBL19198846 | 0.74 | SMN1; SMN2 (0.49) | — | |
| SCHEMBL17662274 | 0.71 | SMN1; SMN2 (0.38) | — | |
| SCHEMBL12108477 | 0.70 | SMN1; SMN2 (0.56) | — | |
| SCHEMBL21648234 | 0.70 | SMN1; SMN2 (0.43) | — | |
| SCHEMBL21648206 | 0.70 | SMN1; SMN2 (0.43) | — | |
| SCHEMBL21648083 | 0.70 | SMN1; SMN2 (0.46) | — | |
| SCHEMBL21648152 | 0.69 | SMN1; SMN2 (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4240579-B1 | METHOD FOR MAKING PHOTOCHROMIC CONTACT LENSES | ALCON INC (CH) | 2024-12-04 | — | — | EP | claimed |
| EP-4622956-A1 | IONIZABLE LIPIDS AND LIPID NANOPARTICLES CONTAINING THEREOF | Certest Biotec, S.L. (ES) | 2025-10-01 | — | — | EP | disclosed |
| WO-2024110381-A1 | IONIZABLE LIPIDS AND LIPID NANOPARTICLES CONTAINING THEREOF | CERTEST BIOTEC, S.L. (ES) | 2024-05-30 | — | — | WO | disclosed |
| EP-4371976-A1 | IONIZABLE LIPIDS AND LIPID NANOPARTICLES CONTAINING THEREOF | Certest Biotec, S.L. (ES) | 2024-05-22 | — | — | EP | disclosed |
| EP-4240579-A1 | METHOD FOR MAKING PHOTOCHROMIC CONTACT LENSES | Alcon Inc. (CH) | 2023-09-13 | — | — | EP | disclosed |
| US-11542492-B2 | Ligand-directed covalent modification of protein | CELGENE CAR LLC (BM) | 2023-01-03 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| WO-2022097049-A1 | METHOD FOR MAKING PHOTOCHROMIC CONTACT LENSES | ALCON INC. (CH) | 2022-05-12 | — | — | WO | disclosed |
| US-20210289794-A1 | COMPOSITIONS AND RELATED METHODS FOR AGRICULTURE | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2021-09-23 | — | — | US | disclosed |
| US-20200031796-A1 | COMPOSITION COMPRISING A COMPOUND OF THIOLACTONE TYPE AND A PARTICULAR SOLVENT AND PROCESS FOR TREATING KERATIN MATERIALS WITH THE COMPOSITION | L'OREAL (FR) | 2020-01-30 | — | — | US | disclosed |
| WO-2018115091-A1 | COMPOSITION COMPRISING BISTHIOLACTONES AND PROCESS FOR TREATING KERATIN MATERIALS USING SAME | L'OREAL (FR) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018115091-A1 | COMPOSITION COMPRISING BISTHIOLACTONES AND PROCESS FOR TREATING KERATIN MATERIALS USING SAME | L'OREAL (FR) | 2018-06-28 | — | — | WO | disclosed |
| US-20170218353-A1 | Ligand-Directed Covalent Modification of Protein | CELGENE CAR LLC (BM) | 2017-08-03 | — | — | US | disclosed |
| EP-2519664-A1 | LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN | Avila Therapeutics, Inc. (US) | 2012-11-07 | — | — | EP | disclosed |
| US-20110269244-A1 | LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN | CELGENE CAR LLC (BM) | 2011-11-03 | — | — | US | disclosed |
| WO-2011082285-A1 | LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN | AVILA THERAPEUTICS, INC. (US) | 2011-07-07 | — | — | WO | disclosed |
| US-5814629-A | FUNGICIDES, BACTERICIDES AND VIRICIDES OF PLANTS | NOVARTIS FINANCE CORPORATION (US) | 1998-09-29 | — | — | US | disclosed |
| EP-0780394-A1 | Microbicides | Novartis AG (CH) | 1997-06-25 | — | — | EP | disclosed |